Tolebrutinib failed to lower disability progression risk in primary progressive MS in a Phase 3 trial, with data shown at ...
Cerebrospinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological ...
Multiple sclerosis (MS) is a chronic disease of the central nervous system. MS disrupts the flow of information between the ...
Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive ...
New clinical trial data suggest vidofludimus calcium can target key mechanisms underlying progressive multiple sclerosis.
Multicenter examination showed biomarkers in cerebrospinal fluid consistently distinguished MS from other ...
MASITINIB HAS UNIQUE AND COMPETITIVE POSITIONING IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS DUE TO ITS DISTINCTIVE SAFETY AND EFFICACY PROFILE AND MECANISM OF ACTIONS TARGETING BOTH MICROGLIA AND MAST ...
Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks ...
AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors, announced that the Japanese Patent Office has formally granted a ...
AB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL 2041 THIS IS THE FIRST COUNTRY DELIVERING THE MS PATENT MASITINIB HAS ...
BOSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results